Holen Sie sich die Stockscreener-App
5.26
1.13%
-0.06
Handel nachbörslich:
5.30
0.04
+0.76%
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara 10-K: Net loss $57.4M, EPS $(1.34); operating loss widens to $64.5M - TradingView
Protara Therapeutics reports $197.9M cash; Q4 net loss $17.3M, FY loss $57.4M - TradingView
Protara Therapeutics: Q4 Earnings Snapshot - Barchart.com
TARA: TARA-002 achieved high response rates in NMIBC, with cash runway into 2028 after a major offering - TradingView
Bladder cancer drug hits 68% response; Protara sees cash runway into 2028 - Stock Titan
Geopolitics Watch: What is the Moat Score of Protara Therapeutics IncWeekly Trend Recap & Verified Momentum Stock Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Millennium Management LLC Acquires Significant Stake in Protara Therapeutics Inc - GuruFocus
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
ASCO-GU 2026: Key Oncology Updates From VIR, TARA, TYRA And Others - RTTNews
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Bladder phase II sinks Protara, LMs phase III wins for Palvella - BioWorld MedTech
Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks
TARA: TARA-002 shows strong efficacy and safety in NMIBC, with high CR rates and durable responses - TradingView
Protara posts positive interim ADVANCED-2 results; TARA-002 shows 68% 6‑month CR in BCG‑unresponsive NMIBC - TradingView
What's Going On With Protara Therapeutics Stock Tuesday?Protara Therapeutics (NASDAQ:TARA) - Benzinga
TARA-002 results send Protara shares upwards - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics stock tumbles on trial data release By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Resul - GuruFocus
Protara Therapeutics stock tumbles on trial data release - Investing.com
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Results - GuruFocus
Protara reports interim results from bladder cancer trial - Investing.com
TARA-002 demonstrates 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer - marketscreener.com
TARA-002 Demonstrates 68% Complete Response Rate at Six - GlobeNewswire
Protara's Experimental Bladder Cancer Drug Shows Encouraging Results - Bitget
Piper Sandler Reaffirms Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Should I average down on Protara Therapeutics Inc. stockBuy Signal & Fast Exit Strategy with Risk Control - mfd.ru
Protara Therapeutics to Participate in Upcoming Investor Conferences - Bitget
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):